Axogen, Inc.

As of June 30, 2026, Axogen, Inc. carries a market capitalization of 2.39B, placing it among publicly traded companies globally. Its enterprise value stands at 2.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Axogen, Inc.'s next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Axogen, Inc. has 53.18M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 8.87, and the price-to-book ratio stands at 9.33.

These figures are as of June 30, 2026. The EV/Sales ratio of 9.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.30B versus a market cap of 2.39B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Axogen, Inc. maintains a current ratio of 6.60, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.83, indicating elevated leverage, while an interest coverage ratio of -0.90 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Axogen, Inc. posted a negative return on equity (ROE) of -18.21, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -13.15, reflecting losses generated across the asset base. The company generates approximately 433,432.27 in revenue per employee across its workforce of 579.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.52 indicates how many times Axogen, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Axogen, Inc.'s stock has gained approximately 107.37% over the past 52 weeks. The 50-day moving average sits at 43.65, while the 200-day moving average is 38.86.

Over the twelve months ended June 30, 2026, Axogen, Inc. generated 251.17M in revenue and converted that into -33.55M in net income, yielding earnings per share of -0.67. EBITDA reached -3.76M, while operating income came in at -12.85M.

As of June 30, 2026, Axogen, Inc. holds 111.41M in cash and equivalents against 20.07M in total debt, resulting in a net debt position of -94.57M. Total book value stands at 256.26M, with working capital of 170.00M providing operational flexibility.

Axogen, Inc. produced 15.05M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -8.54M in capital expenditures, free cash flow totaled 6.51M - equivalent to 0.13 per share.

Over the twelve months ended June 30, 2026, Axogen, Inc. posted a gross margin of 74.56, reflecting its pricing power and cost economics. The operating margin of -5.12 and net profit margin of -13.36 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.29, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -2.96, meaning Axogen, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Axogen, Inc.'s most recent stock split took place on July 11, 1994 with a 20:21 split ratio.

As of June 30, 2026, Axogen, Inc. has an Altman Z-Score of 29.35, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.